Catabasis Pharmaceuticals to Present Data for Hypercholesterolemia Product Candidate, CAT-2054, at the 17th International Symposium on Atherosclerosis

CAMBRIDGE, Mass.--()--Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that CAT-2054, the Company’s product candidate targeting the Sterol Regulatory Element Binding Protein, or SREBP, pathway for the potential treatment of hypercholesterolemia, will be featured in an oral presentation at the upcoming International Symposium on Atherosclerosis. The presentation will include data from the single ascending dose portion of the Phase 1 study of CAT-2054 in healthy volunteers. The International Symposium on Atherosclerosis will be held May 23 - 26, 2015, in Amsterdam, the Netherlands, at Amsterdam RAI Congress Centre.

  • Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, will give a presentation titled “Phase 1 Study of CAT-2054, a Novel Oral Modulator of Sterol Response Element Binding Protein.” The oral presentation will take place on Sunday, May 24, 2015, from 11:45am to 12:00pm local time as part of the session titled “Clinical Breakthroughs: A plethora of new therapeutic targets.”

About CAT-2054
CAT-2054 is an investigational oral drug being initially developed for the treatment of hypercholesterolemia in patients for whom existing therapies are insufficient. By modulating the SREBP pathway, CAT-2054 may inhibit production of important cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase and NPC1L1. CAT-2054, if approved, may have the potential to be the first therapy to simultaneously modulate cholesterol synthesis, clearance and absorption. In January 2015, a Phase 1 clinical trial was initiated to assess the safety, tolerability and pharmacokinetics of CAT-2054 in healthy volunteers.

About Catabasis

Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company's SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company's technology and pipeline of drug candidates, please visit www.catabasis.com.

Contacts

Corporate and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com

Release Summary

Catabasis' CAT-2054 candidate targeting the SREBP pathway for the potential treatment of hypercholesterolemia will be featured in a presentation at the International Symposium on Atherosclerosis.

Contacts

Corporate and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com